Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 503 clinical trials
A Phase 1b Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Subjects With Multiple Myeloma

The purpose of this study is to identify recommended Phase 2 doses (RP2Ds) for each treatment combination (between daratumumab plus talquetamab and teclistamab plus daratumumab with or without pomalidomide) and to characterize the safety of each RP2D for selected treatment combinations.

daratumumab
immunoglobulins
measurable disease
human chorionic gonadotropin
serum immunoglobulin a
  • 114 views
  • 27 Oct, 2022
  • 22 locations
A Phase 2 Study of Daratumumab Subcutaneous (Dara-SC) Administration in Combination With Carfilzomib and Dexamethasone (DKd) Compared With Carfilzomib and Dexamethasone (Kd) in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab to Evaluate Daratumumab Retreatment

The purpose of this study is to compare the efficacy (rate of very good partial response [VGPR] or better as best response as defined by the International Myeloma Working Group [IMWG] criteria) of daratumumab subcutaneous (Dara-SC) in combination with carfilzomib and dexamethasone (Kd) with the efficacy of Kd in participants …

daratumumab
corticosteroids
refractory multiple myeloma
cell transplantation
progressive disease
  • 30 views
  • 21 Oct, 2022
  • 110 locations
A Phase 1b Dose Escalation Study of the Combination of the Bispecific T Cell Redirection Antibodies Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma (RedirecTT-1)

The purpose of this study is to identify the recommended Phase 2 regimen(s) (RP2R[s]) and schedule for the study treatment (Part 1) and to characterize the safety of the RP2R(s) for the study treatment (Part 2). The RP2R(s) will describe the combination doses and schedules of (tal+tec+dara) the treatment combinations …

lenalidomide
human chorionic gonadotropin
refractory multiple myeloma
carfilzomib
bortezomib
  • 5 views
  • 25 Oct, 2022
  • 13 locations
Study on Tailored Treatment in Elderly Patients With Newly Diagnosed Primary Lymphoma of Central Nervous System (FIORELLA)

Primary central nervous system lymphomas are rare aggressive malignancies, usually treated in two steps: an induction phase (where a combination of chemotherapy is given) followed by a consolidation phase (where patients usually receive one of the following: whole-brain irradiation, chemotherapy supported by autologous stem-cell transplantation, other type of chemotherapy, or …

maintenance treatment
temozolomide
lenalidomide
rituximab
cancer
  • 0 views
  • 13 May, 2022
  • 35 locations
A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL

This multicenter, prospective, open-label, randomized, superiority phase 3 study is designed to demonstrate that treatment with a triple combination of acalabrutinib, obinutuzumab and venetoclax (GAVe) prolong the progression-free survival (PFS) as compared to treatment with the combination of obinutuzumab and venetoclax (GVe) in pa-tients with high risk CLL (defined as …

obinutuzumab
platelet count
venetoclax
acalabrutinib
gilbert's syndrome
  • 0 views
  • 27 May, 2022
  • 2 locations
A Multi-center, Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment

The purpose of this study is to evaluate the safety and efficacy of deucravacitinib versus placebo for the treatment of participants with active PsA who are naïve to biologic disease modifying antirheumatic drugs or had previously received TNFα inhibitor treatment.The long term extension period will provide additional long-term safety and …

anti-rheumatic drugs
apremilast
plaque psoriasis
arthritis
biological drug
  • 1 views
  • 11 Oct, 2022
  • 107 locations
Haploidentical Donor vs mMUD in Hematological Malignancies (HAMLET)

The goal of this trial is to compare the outcome after partially matched (single mismatch) unrelated donor transplantation with haploidentical transplantation in a randomized controlled setting.

neoadjuvant therapy
remission
cell transplantation
b-cell acute lymphoblastic leukemia
ejection fraction
  • 11 views
  • 13 Feb, 2022
  • 9 locations
CAR-37 T Cells In Hematologic Malignancies

This research study is studying Chimeric Antigen Receptor (CAR)-37 T Cells (CAR-37 T Cells) for treating people with relapsed or refractory CD37+ hematologic malignancies and to understand the

cancer treatment
neutrophil count
bone marrow procedure
apheresis
peripheral t-cell lymphoma
  • 0 views
  • 09 Nov, 2021
Sexual Health in Patients With Hematologic Malignancies

characterized by a disruption in one or more elements of the response cycle. Previous research shows that patients with hematologic malignancies and specifically patients following stem cell transplantation

  • 0 views
  • 25 Mar, 2022
FT516 in Subjects With Advanced Hematologic Malignancies

This is a Phase 1/1b dose-finding study of FT516 as monotherapy in acute myeloid leukemia (AML) and in combination with CD20 directed monoclonal antibodies in B-cell lymphoma. The study includes three stages: dose escalation, safety confirmation, and dose expansion.

neoadjuvant therapy
refractory acute myeloid leukemia (aml)
leukemia
cyclophosphamide
hematologic malignancy
  • 19 views
  • 04 Oct, 2022
  • 7 locations